The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS
February 03, 2022 08:00 AM Eastern Standard Time CALGARY, Alberta & TORONTO–(BUSINESS WIRE)–The Canadian Neuromuscular Disease Registry (CNDR), an independent, academic registry based out of the University of Calgary, and...